Global supply chain stabilization in 2024 underpins the BSX stock forecast, minimizing input cost volatility and supporting predictable earnings flow. Our free Boston Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Boston Scientific's overall financial health at a glance. Further, Boston Scientific is currently looking forward to closing the acquisitions of SoniVie, which has developed a clinical-stage differentiated ultrasound-based renal denervation technology, and Intera Oncology, which will broaden its interventional oncology offerings to patients with liver cancer. Recent sector rotation into medical technology has tightened spreads for BSX, making the BSX stock forecast more compelling for medium‑term investors seeking defensive growth.